A randomized, open labeled, multicenter study comparing entecavir versus lamivudine as antiviral prophylaxis for patients with hepatitis B infection undergoing cytotoxic chemotherapy for malignant tumors
Phase of Trial: Phase III
Latest Information Update: 03 Jul 2017
At a glance
- Drugs Entecavir (Primary) ; Lamivudine
- Indications Hepatitis B
- Focus Therapeutic Use
- Acronyms APPLE
- 28 Jun 2017 Status changed from recruiting to completed.
- 10 Jun 2017 Biomarkers information updated
- 03 May 2017 Planned primary completion date changed from 1 Dec 2016 to 1 Jun 2017.